Article

The Austrian MS Database and the Austrian MS Cohort – a national effort towards data harmonization and prospective data collection

2025-02-23

Abstract excerpt

<h4>Background</h4> A variety of disease-modifying therapies (DMTs) are now available for multiple sclerosis (MS), each with distinct efficacy and risk profiles. However, the clinical course of MS varies significantly both within and between individuals, and the optimal treatment strategy remains uncertain at the group and individual levels. Addressing questions about treatment strategies through traditional rand...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b93a4526-638d-5509-9262-2aa1d64c6352
DOI: 10.1101/2025.02.17.25322422

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The Austrian MS Database and the Austrian MS Cohort – a national effort towards data harmonization and prospective data collectionDOI 10.1101/2025.02.17.25322422Read

From Fragmented Evidence to a Unified GCC Demyelinating Disease Registry: A Strategic Framework for MS, NMOSD, MOGAD, Optic Neuritis, LETM, and Pediatric Acquired DemyelinationSemantic proximity Read

Multiple sclerosis and neuromyelitis optica spectrum disorders in Argentina: comparing baseline data from the Argentinean MS Registry (RelevarEM).Semantic proximity Read

Landscape of MS patient cohorts and registries: Recommendations for maximizing impact.Semantic proximity Read

SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.Semantic proximity Read

United Europeans for development of pharmacogenomics in multiple sclerosis network.Semantic proximity Read

Current status and future opportunities in modeling Multiple Sclerosis clinical characteristicsSemantic proximity Read

Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation.Semantic proximity Read

Associations of DMT therapies with COVID-19 severity in multiple sclerosisSemantic proximity Read

Advancing data science in drug development through an innovative computational framework for data sharing and statistical analysisSemantic proximity Read

Associations of DMT Therapies with COVID-19 Severity in Multiple Sclerosis: An International Cohort StudySemantic proximity Read

Multiple sclerosis by phenotype in Germany.Semantic proximity Read

Ocrelizumab versus Natalizumab in Relapsing-Remitting Multiple Sclerosis: A Registry-Linked Electronic Health Records StudySemantic proximity Read